Shionogi closer to antiviral approval in COVID-19

28 September 2022

Japanese drugmaker Shionogi (TYO: 4507) closed 1% higher after Tokyo trading on Wednesday, after reporting progress with its COVID-19 antiviral.

The Osaka-based firm announced that ensitrelvir fumaric acid, an investigational, 3CL protease inhibitor, which is being administered once daily for five days as an antiviral treatment for COVID-19, achieved the primary endpoint in the Phase III part of a Phase II/III study conducted in Asia.

This study was conducted in patients with mild and moderate symptoms of COVID-19 and assessed clinical symptom resolution with ensitrelvir compared to placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK